| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000035205 |
| Receipt No. | R000040088 |
| Scientific Title | A clinical study to evaluate the effects of the Linablue tablet on skin function |
| Date of disclosure of the study information | 2020/03/31 |
| Last modified on | 2021/12/15 (Ver. 5) |
| Basic information | ||
| Public title | A clinical study to evaluate the effects of the Linablue tablet on skin function | |
| Acronym | A clinical study to evaluate the effects of the Linablue tablet on skin function | |
| Scientific Title | A clinical study to evaluate the effects of the Linablue tablet on skin function | |
| Scientific Title:Acronym | A clinical study to evaluate the effects of the Linablue tablet on skin function | |
| Region |
|
|
| Condition | |||
| Condition | Healthy volunteers | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To evaluate the effects of the Linablue tablet on skin function in a randomized, double-blind, placebo-controlled, parallel-group comparative study |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Transepidermal Water Loss (TEWL) |
| Key secondary outcomes | Hydration level of the skin surface
Elasticity of the upper skin layer Skin replica analysis (wrinkles and texture) Microscopic analysis by the dermatologist (wrinkles and spots) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake of the test food (tablets that contain Linablue ) for 8 weeks | |
| Interventions/Control_2 | Intake of the placebo (tablets that don't contain Linablue) for 8 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1)Healthy females whose age of 20 years or more and less than 65 years
2)Subjects who experience dry skin 3)Subjects having a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent |
|||
| Key exclusion criteria | 1)Subjects who are dermatological patients
2)Subjects receiving a medical treatment for serious renal, hepatic, cardio-vascular, respiratory, endocrine or metabolic disorders or having a medical history of these disorders 3)Subjects having the possibility of developing allergic symptoms by the test food 4)Subjects taking regularly foods for specified health uses, foods with function claims labeled, medicines or quasi-drugs having the effects on skin function 5)Subjects who are pregnant or lactating, or intending to become pregnant during the study 6)Subjects who took part in another clinical study within 3 months prior to the start of the present study or who are currently taking part in another clinical study 7)Subjects deemed unsuitable by the investigator |
|||
| Target sample size | 96 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | DIC Corporation | ||||||
| Division name | Application Materials Technology & Production Group | ||||||
| Zip code | 290-8585 | ||||||
| Address | 12, Yawatakaigandori, Ichihara, Chiba | ||||||
| TEL | 0436-41-4128 | ||||||
| yasuyuki-imai@ma.dic.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Soiken Inc. | ||||||
| Division name | R&D Division | ||||||
| Zip code | 560-0082 | ||||||
| Address | Senri Life Science Center 13F, 1-4-2,Shinsenri-higashimachi, Toyonaka, Osaka | ||||||
| TEL | 06-6871-8888 | ||||||
| Homepage URL | |||||||
| sugino@soiken.com | |||||||
| Sponsor | |
| Institute | Soiken Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | IRB of Fukuda Clinic |
| Address | Shin-OsakaBrick Building 2F, 1-6-1, Miyahara,Yodogawa-ku, Osaka, Osaka |
| Tel | 06-6398-0203 |
| fukudaclinicIRB@gmail.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | https://mol.medicalonline.jp/archive/search?jo=ai6yrtyb&ye=2019&vo=47&issue=11 |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | https://mol.medicalonline.jp/archive/search?jo=ai6yrtyb&ye=2019&vo=47&issue=11 | ||||||
| Number of participants that the trial has enrolled | 96 | ||||||
| Results | https://mol.medicalonline.jp/archive/search?jo=ai6yrtyb&ye=2019&vo=47&issue=11 | ||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results | |||||||
| Baseline Characteristics | Test food group
female n=48 age: mean 45.1, SD 8.3 years Placebo group female n=48 age: mean 45.2, SD 10.9 years |
||||||
| Participant flow | Screening examination n=96
Enrollment n=96 Randomization n=96 Analysis n=93 |
||||||
| Adverse events | In the intake period, 8 and 11 adverse events were individually noted in the test food group and placebo group, respectively, and adverse events were not severe or related to the administration of the test food. | ||||||
| Outcome measures | Transepidermal Water Loss(TEWL)
Hydration level of the skin surface Elasticity of the upper skin layer Skin replica analysis (wrinkles and texture) Microscopic analysis by the dermatologist (wrinkles and spots) |
||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040088 |